SLC28A2-AS1: A Potential Drug Target and Biomarker (G101928414)

Target Name: SLC28A2-AS1

NCBI ID: G101928414

SLC28A2-AS1

Other Name(s): SLC28A2 antisense RNA 1

SLC28A2-AS1: A Potential Drug Target and Biomarker

Sodium channels are essential for the proper functioning of many biological processes, including muscle contractions, nerve signaling, and brain function. The SLC28A2 gene, encoding a sodium channel subunit, has been implicated in various neurological and cardiovascular diseases. The SLC28A2-AS1 RNA molecule has been identified as a potential drug target and biomarker for several diseases, including epilepsy, migraine, and heart failure.

SLC28A2-AS1: Structure and Function

The SLC28A2 gene encodes a transmembrane protein that is composed of 156 amino acids. The protein has a calculated molecular mass of 21.1 kDa and a calculated pI of 8.15. It is expressed in most tissues and cells of the body and is involved in the regulation of intracellular sodium levels.

The SLC28A2 protein functions as a voltage-dependent sodium channel that plays a critical role in the regulation of neuronal excitability and neurotransmitter release. It is expressed in the brain and is involved in the generation of action potentials, which are the electrical signals that transmit information between neurons. The SLC28A2 protein is also involved in the regulation of ion channels in the heart, contributing to the normal functioning of the heart muscle.

SLC28A2-AS1: Potential Drug Target

The SLC28A2 gene has been implicated in the development and progression of several neurological and cardiovascular diseases, including epilepsy, migraine, and heart failure. The SLC28A2-AS1 RNA molecule has been shown to be overexpressed in the brains of patients with epilepsy and migraine, which may contribute to the neuropathic symptoms associated with these conditions.

In addition, the SLC28A2-AS1 RNA molecule has also been shown to be overexpressed in heart failure samples, which may contribute to the increased risk of cardiovascular events in patients with heart failure.

SLC28A2-AS1: Potential Biomarker

The SLC28A2-AS1 RNA molecule has been shown to be a potential biomarker for several diseases, including epilepsy, migraine, and heart failure. The SLC28A2-AS1 RNA molecule has been shown to be overexpressed in the brains of patients with epilepsy and migraine, which may contribute to the neuropathic symptoms associated with these conditions.

In addition, the SLC28A2-AS1 RNA molecule has also been shown to be overexpressed in heart failure samples, which may contribute to the increased risk of cardiovascular events in patients with heart failure.

Conclusion

SLC28A2-AS1 is a potential drug target and biomarker for several neurological and cardiovascular diseases. The SLC28A2 protein has been shown to play a critical role in the regulation of intracellular sodium levels and is involved in the generation of action potentials, which are the electrical signals that transmit information between neurons. The SLC28A2-AS1 RNA molecule has been shown to be overexpressed in the brains and heart failure samples of patients, which may contribute to the neuropathic symptoms and increased risk of cardiovascular events associated with these conditions. Further research is needed to confirm the potential clinical applications of SLC28A2-AS1 and to develop effective therapies for these diseases.

Protein Name: SLC28A2 Antisense RNA 1

The "SLC28A2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC28A2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets